Vaccines Market
Vaccines Market - Global Industry Assessment & Forecast
#
Pages:
141
Base Year:
2022
Apr - 2022
Format:
Report Code:
VMR-1508
Segments Covered
By
Technology (excluding COVID 19 vaccines) Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, Toxoid vaccines, Viral vector vaccines
-
By
Technology (including COVID 19 vaccines) mRNA vaccines, Viral Vector vaccines, Others
-
By
Type Monovalent vaccines, Multivalent vaccines
-
By
Disease Indication Influenza, Pneumococcal diseases, Combination vaccines, HPV, Herpes Zoster, Meningococcal diseases, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, COVID 19, Others
-
By
Route of Administration Intramuscular & Subcutaneous administration, Oral administration, Others
-
By
End-user Pediatric vaccines, Adult vaccines
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 43.80 Billion |
 Revenue 2030:
|
USD 90.52 Billion |
 Revenue CAGR
(2023 - 2030): |
9.50% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Vaccines Market Segment Analysis
- Vaccines Technology (excluding COVID 19 vaccines) Outlook (Revenue, USD Million, 2018 - 2030)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Vaccines Technology (including COVID 19 vaccines) Outlook (Revenue, USD Million, 2018 - 2030)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Vaccines Type Outlook (Revenue, USD Million, 2018 - 2030)
- Monovalent vaccines
- Multivalent vaccines
- Vaccines Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Vaccines Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Vaccines End-user Outlook (Revenue, USD Million, 2018 - 2030)
- Pediatric vaccines
- Adult vaccines
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
-
North America Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
-
North America Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
-
North America Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
-
North America Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
-
North America Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- U.S.
- U.S. Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- U.S. Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- U.S. Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- U.S. Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- U.S. Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- U.S. Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- U.S. Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Canada
- Canada Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Canada Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Canada Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Canada Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Canada Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Canada Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Canada Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Mexico
- Mexico Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Mexico Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Mexico Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Mexico Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Mexico Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Mexico Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Mexico Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
North America Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Europe
-
Europe Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
-
Europe Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
-
Europe Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
-
Europe Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
-
Europe Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
-
Europe Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- U. K.
- U.K. Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- U.K. Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- U.K. Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- U.K. Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- U.K. Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- U.K. Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- U.K. Vaccines Market, by Technology (excluding COVID 19 vaccines)
- France
- France Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- France Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- France Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- France Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- France Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- France Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- France Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Germany
- Germany Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Germany Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Germany Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Germany Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Germany Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Germany Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Germany Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Italy
- Italy Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Italy Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Italy Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Italy Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Italy Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Italy Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Italy Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Spain
- Spain Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Spain Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Spain Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Spain Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Spain Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Spain Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Spain Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Rest of Europe
- Rest of Europe Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Rest of Europe Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Rest of Europe Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Rest of Europe Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Rest of Europe Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Rest of Europe Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Rest of Europe Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Europe Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Asia Pacific
-
Asia Pacific Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
-
Asia Pacific Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
-
Asia Pacific Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
-
Asia Pacific Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
-
Asia Pacific Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
-
Asia Pacific Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- China
- China Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- China Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- China Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- China Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- China Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- China Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- China Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Japan
- Japan Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Japan Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Japan Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Japan Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Japan Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Japan Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Japan Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Germany
- Germany Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Germany Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Germany Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Germany Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Germany Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Germany Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Germany Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
India
- India Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- India Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- India Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- India Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- India Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- India Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- India Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
South Korea
- South Korea Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- South Korea Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- South Korea Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- South Korea Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- South Korea Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- South Korea Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- South Korea Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
South East Asia
- South East Asia Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- South East Asia Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- South East Asia Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- South East Asia Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- South East Asia Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- South East Asia Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- South East Asia Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Rest of Asia Pacific
- Rest of Asia Pacific Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Rest of Asia Pacific Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Rest of Asia Pacific Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Rest of Asia Pacific Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Rest of Asia Pacific Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Rest of Asia Pacific Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Rest of Asia Pacific Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Asia Pacific Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Latin America
-
Latin America Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
-
Latin America Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
-
Latin America Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
-
Latin America Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
-
Latin America Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
-
Latin America Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Brazil
- Brazil Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Brazil Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Brazil Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Brazil Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Brazil Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Brazil Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Brazil Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Argentina
- Argentina Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Argentina Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Argentina Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Argentina Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Argentina Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Argentina Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Argentina Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Rest of Latin America
- Rest of Latin America Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Rest of Latin America Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Rest of Latin America Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Rest of Latin America Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Rest of Latin America Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Rest of Latin America Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Rest of Latin America Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Latin America Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Middle East & Africa
-
Middle East & Africa Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
-
Middle East & Africa Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
-
Middle East & Africa Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
-
Middle East & Africa Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
-
Middle East & Africa Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
-
Middle East & Africa Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- GCC Countries
- GCC Countries Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- GCC Countries Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- GCC Countries Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- GCC Countries Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- GCC Countries Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- GCC Countries Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- GCC Countries Vaccines Market, by Technology (excluding COVID 19 vaccines)
- South Africa
- South Africa Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- South Africa Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- South Africa Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- South Africa Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- South Africa Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- South Africa Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- South Africa Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Vaccines Market, by Technology (excluding COVID 19 vaccines)
- Conjugate vaccines
- Inactivated & Subunit vaccines
- Live Attenuated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Viral vector vaccines
- Rest of Middle East & Africa Vaccines Market, by Technology (including COVID 19 vaccines)
- mRNA vaccines
- Viral Vector vaccines
- Others
- Rest of Middle East & Africa Vaccines Market, by Type
- Monovalent vaccines
- Multivalent vaccines
- Rest of Middle East & Africa Vaccines Market, by Disease Indication
- Influenza
- Pneumococcal diseases
- Combination vaccines
- HPV
- Herpes Zoster
- Meningococcal diseases
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- COVID 19
- Others
- Rest of Middle East & Africa Vaccines Market, by Route of Administration
- Intramuscular & Subcutaneous administration
- Oral administration
- Others
- Rest of Middle East & Africa Vaccines Market, by End-user
- Pediatric vaccines
- Adult vaccines
- Rest of Middle East & Africa Vaccines Market, by Technology (excluding COVID 19 vaccines)
-
Middle East & Africa Vaccines Market, by Technology (excluding COVID 19 vaccines)
- North America
FAQ
Frequently Asked Question
What is the global demand for Vaccines in terms of revenue?
-
The global Vaccines valued at USD 43.80 Billion in 2022 and is expected to reach USD 90.52 Billion in 2030 growing at a CAGR of 9.50%.
Which are the prominent players in the market?
-
The prominent players in the market are GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer Inc. (US), Sanofi SA (France), CSL Limited (Australia), Emergent BioSolutions Inc. (US), Johnson & Johnson (US), AstraZeneca plc (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India), Novavax Inc. (US), FSUE NPO Microgen (Russia), Sinovac Biotech, Ltd. (China), Incepta Vaccine Limited (Bangladesh), Valneva SE (France), VBI Vaccines (US), PT Bio Farma (Persero) (Indonesia), Inovio Pharmaceuticals Inc. (US), Chongqing Zhifei Biological Products Co., Ltd. (China), Indian Immunologicals Limited (India)..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 9.50% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Vaccines include
- Growing prevalence of emerging and re-emerging infectious diseases
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Vaccines in 2022.
